Should the hematocrit be normalized in dialysis and in pre-ESRD patients?
Macdougall
I C
IC
Department of Renal Medicine, King's College Hospital, London, UK. icm-kru@globalnet.co.uk
D000328:Adult; D000368:Aged; D000740:Anemia / Q000191:economics / Q000209:etiology / Q000517:prevention & control*; D002648:Child; D015897:Comorbidity; D016527:Drug Costs; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006400:Hematocrit; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D007501:Iron / Q000191:economics / Q000627:therapeutic use; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000191:economics / Q000628:therapy; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009203:Myocardial Infarction / Q000517:prevention & control; D009790:Occupations; D010530:Peritoneal Dialysis; D010809:Physical Fitness; D017410:Practice Guidelines as Topic; D011788:Quality of Life; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D012016:Reference Values; D006435:Renal Dialysis; D019851:Thrombophilia / Q000139:chemically induced; D016896:Treatment Outcome
D006454:Hemoglobins; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa; D007501:Iron